Free Trial
NASDAQ:SPRO

Spero Therapeutics (SPRO) Stock Price, News & Analysis

Spero Therapeutics logo
$0.58 -0.04 (-6.73%)
Closing price 04:00 PM Eastern
Extended Trading
$0.60 +0.02 (+3.44%)
As of 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Spero Therapeutics Stock (NASDAQ:SPRO)

Key Stats

Today's Range
$0.56
$0.63
50-Day Range
$0.58
$0.90
52-Week Range
$0.57
$1.75
Volume
286,902 shs
Average Volume
188,756 shs
Market Capitalization
$32.53 million
P/E Ratio
8.32
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Moderate Buy

Company Overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Remove Ads

Spero Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

SPRO MarketRank™: 

Spero Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 150th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Spero Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Spero Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Spero Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Spero Therapeutics are expected to grow in the coming year, from ($1.20) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Spero Therapeutics is 8.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.03.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Spero Therapeutics is 8.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.20.

  • Price to Book Value per Share Ratio

    Spero Therapeutics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Spero Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.84% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently increased by 2.97%, indicating that investor sentiment is decreasing.
  • Percentage of Shares Shorted

    0.84% of the float of Spero Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Spero Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Spero Therapeutics has recently increased by 2.97%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Spero Therapeutics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    3 people have added Spero Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Spero Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $191,288.00 in company stock.

  • Percentage Held by Insiders

    Only 4.52% of the stock of Spero Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 25.60% of the stock of Spero Therapeutics is held by institutions.

  • Read more about Spero Therapeutics' insider trading history.
Receive SPRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SPRO Stock News Headlines

TD Cowen Sticks to Their Hold Rating for Spero Therapeutics (SPRO)
Three new patents reveal Elon and Trump’s secret “Project America”
Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR! He says these 5 stocks are trading for less than $2 right now… But they could soon SOAR in Trump’s first 100 days.
Spero Therapeutics reports Q4 EPS (38c), consensus (31c)
See More Headlines

SPRO Stock Analysis - Frequently Asked Questions

Spero Therapeutics' stock was trading at $1.03 at the beginning of the year. Since then, SPRO shares have decreased by 43.5% and is now trading at $0.5820.
View the best growth stocks for 2025 here
.

Spero Therapeutics, Inc. (NASDAQ:SPRO) announced its quarterly earnings results on Thursday, March, 27th. The company reported ($0.38) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.03. The company had revenue of $15.04 million for the quarter, compared to the consensus estimate of $12.40 million. Spero Therapeutics had a trailing twelve-month return on equity of 4.03% and a net margin of 3.30%.

Spero Therapeutics (SPRO) raised $75 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

Shares of SPRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Spero Therapeutics investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), NVIDIA (NVDA), Editas Medicine (EDIT) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
3/27/2025
Today
4/04/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SPRO
Fax
N/A
Employees
150
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$5.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+738.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
8.53
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$22.81 million
Pretax Margin
3.39%

Debt

Sales & Book Value

Annual Sales
$27.40 million
Cash Flow
$0.37 per share
Price / Cash Flow
1.62
Book Value
$2.02 per share
Price / Book
0.30

Miscellaneous

Free Float
52,054,000
Market Cap
$33.32 million
Optionable
Optionable
Beta
0.64

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:SPRO) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners